Search for on  
Saturday, November 07, 2009
     
 Home
 About CWA
 Join CWA
 Give/Donate
- Donate Now
- More Ways to Give
 Get Involved
- Federal
- State/Local
 Media Center
- CWA Experts
- Press Releases
- CWA In The News
- CWA Op/Eds
 Legislation
 Beverly LaHaye
 Institute
 Culture and Family Issues
 Legal Studies
 Family Voice
- Subscribe Online!
 Multimedia
 Shop CWA
 About CWA
 CWALAC
 Project 535
 Employment
 Internships
 Brochures
 Fact Cards
 Recently on CWA
 Links

CWA of Iowa – Veterans Event
November 9, 2009
Des Moines, IA

CWA of Hawaii – Now is the Time – Now More Than Ever
November 9, 2009
Hilo, HI

CWA of Central California – Beyond the TEA Parties
November 14, 2009
San Jose, CA

CWA of Iowa – National Day of Fasting, Repentance & Prayer
November 19, 2009
State Wide


 

CWA: RU-486 Claims Two More Women’s Lives     3/17/2006

Concerned Women for America (CWA) expressed outrage that the Food and Drug Administration (FDA) still refuses to pull the abortion pill RU-486 from the market even after announcing today that two more women who took the drug have died.

“The FDA has pulled other drugs that have caused fewer deaths and less severe complications than RU-486. Why the double-standard for an abortion drug that is now linked to the deaths of seven healthy women and over 800 other reported complications?” stated Wendy Wright, president of CWA.

The FDA admits that only 10 percent of complications suffered by patients from drugs get reported. Over 800 complications due to RU-486 have been reported to the FDA.

“Two more families are grieving because the FDA refuses to pull this dangerous drug from the market,” said Wright. “By giving its approval, FDA participates in the deception that RU-486 is ‘safe.’ How many women must die before the FDA will act? Are their lives less important than making abortion convenient?”

Drugs with fewer reported complications that the FDA has pulled include:

NeutroSpec, an imaging agent used to diagnose internal infections, was pulled from the market after being linked to two deaths, 20 severe reactions, and 46 other “less” severe reactions.

Tysabri, a drug to treat multiple sclerosis, was pulled from the market on Feb. 28, 2005, after reports that three patients taking it had developed PML, a rare brain disease. Studies published in New England Journal of Medicine in early March reported no additional cases of PML.

Lotronex, the only drug in its class to treat irritable bowel syndrome (IBS), which afflicts approximately 40 million Americans was pulled. About 300,000 people had taken it. About 70 patients had developed severe problems, with five deaths including three possibly linked to the drug.

Bextra was pulled even though an FDA advisory committee voted a few months before that Bextra should remain on the market.

“The FDA has acted cautiously with these other drugs,” stated Miss Wright. “Why is that same caution not exercised with a drug that only women use, and it’s only purpose is to abort a baby?”



Bookmark and Share

For Information Contact:
Demi Bardsley
(202) 309-5978
media.cwfa.org

Printer Friendly Version

Recent Articles
Knock, Knock: We’re Here!
CWA joins Michele Bachmann's 'House Call' on Congress
Pelosi’s Bill Supported by Partial-Birth Abortionist
Now's the Time to Stop the Abomination of ObamaCare
ObamaCare = Coerced Abortions
Petitions Against Federal Funding of Abortion Delivered to Capitol Hill
ObamaCare and the Doctor Shortage
40 Days for Life
Testimony Before the Senate Health, Education, Labor, and Pensions Committee
"Defender La Vida Juntos: Defending Life Together"
American Pro-Lifers to Greet Spain’s Prime Minister

 

 
 

 

Concerned Women for America
1015 Fifteenth St. N.W., Suite 1100
Washington, D.C. 20005
Phone: (202) 488-7000
Fax: (202) 488-0806

Feedback / Questions? || Problem with this page? || Archives



 
    ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... .....